Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	52.74	53.4	65.49	47.64	38.35
Revenue Growth (YoY)	-1.23%	-18.47%	37.48%	24.22%	-39.03%
Cost of Revenue	26.99	24.32	22.98	19.59	16.35
Gross Profit	25.75	29.08	42.51	28.05	22
Selling, General & Admin	11.68	12.19	14.96	11.71	12.73
Research & Development	19.57	12.97	17.09	29.35	29.73
Total Operating Expenses	31.25	25.16	32.05	41.06	42.46
Operating Income	-5.5	3.92	10.46	-13.01	-20.46
Interest Income	1.08	1.3	1.29	1.15	0.4
Interest Expense	-1.19	-1.06	-3.18	-2.53	-7.52
Total Non-Operating Income (Expense)	-0.11	0.24	-1.89	-1.38	-7.12
Pretax Income	-5.61	4.15	8.57	-14.4	-27.58
Provision for Income Taxes	1	1.22	0.25	0.53	-
Net Income	-6.6	2.93	8.31	-14.93	-27.58
Net Income to Common	-6.6	2.93	8.31	-14.93	-27.58
Net Income Growth	-	-64.73%	-	-	-
Shares Outstanding (Basic)	79	73	68	48	44
Shares Outstanding (Diluted)	79	81	82	48	44
Shares Change (YoY)	-3.10%	-1.66%	70.04%	9.81%	51.43%
EPS (Basic)	-0.08	0.04	0.12	-0.31	-0.62
EPS (Diluted)	-0.08	0.04	0.09	-0.31	-0.62
EPS Growth	-	-55.56%	-	-	-
Shares Outstanding	80.43	75.85	72.95	53.79	45.56
Free Cash Flow	-13.63	7.39	-2.47	-25.63	-11.74
Free Cash Flow Per Share	-0.17	0.09	-0.03	-0.53	-0.27
Gross Margin	48.82%	54.46%	64.91%	58.87%	57.37%
Operating Margin	-10.43%	7.34%	15.97%	-27.32%	-53.36%
Profit Margin	-12.52%	5.49%	12.69%	-31.33%	-71.92%
FCF Margin	-25.84%	13.84%	-3.77%	-53.80%	-30.62%
EBITDA	-4.04	5.22	11.65	-11.93	-19.34
EBITDA Margin	-7.65%	9.78%	17.79%	-25.04%	-50.44%
EBIT	-5.5	3.92	10.46	-13.01	-20.46
EBIT Margin	-10.43%	7.34%	15.97%	-27.32%	-53.36%
Effective Tax Rate	-17.76%	29.42%	2.97%	-3.68%	0.00%

Updated Mar 18, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q